Skip to main content
Premium Trial:

Request an Annual Quote

MBL Inks Pact with Envoy, Provides Access to RIP-Chip

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Medical & Biological Laboratories today announced it has signed a non-exclusive agreement with Envoy Therapeutics to provide it access to MBL's RIP-Chip technology.

Under the terms of the deal, MBL will receive an upfront payment of an undisclosed amount, annual licensing fees and potential milestone payments. Envoy will use the RIP-Chip for drug discovery and development.

Further terms of the deal were not disclosed.

MBL's RIP-Chip is for RNA-binding protein immunoprecipitation for microarray, sequencing, and PCR applications, according to the company's website. The technology is the only high-throughput approach for direct elucidation of complex molecular networks involving genes, DNA, RNA, microRNA, proteins, and RNA localization as mediated by specific binding proteins.

The importance of such networks has become increasingly evident with "the growing appreciation of RNAi therapy, drug discovery, and the role of RNA utilization in determining normal and disease outcomes," MBL said in a statement

MBL is based in Nagoya, Japan and develops solutions and clinical diagnostics. Envoy, headquartered in Jupiter, Fla., develops therapeutics with technology that combines genetic engineering with new molecular biology methods for labeling and extracting protein-making components of specific cell types.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.